Pharmaceuticals (Therapeutic Medications)
- Code of Federal Regulations
- First-Class Airman Medical Certificate: 67.113(c)
- Second-Class Airman Medical Certificate: 67.213(c)
- Third-Class Airman Medical Certificate: 67.313(c)
side-effects, even weeks after the drug is discontinued. Because of the association with adverse neuropsychiatric side-effects, even weeks after discontinuation, a pilot or ATCS who elects to use mefloquine for malaria prophylaxis or who contracts malaria and is treated with mefloquine will be disqualified for pilot/ATCS duties for the duration of use of mefloquine and for 4 weeks after the last dose. In this instance, the pilot or ATCS must contact the FAA or his/her Aviation Medical Examiner prior to returning to flight duties after use (Agency ATCSs must contact an agency flight surgeon).
- Use of mefloquine must be discontinued for at least 4 weeks prior to consideration and:
- The airman or contract tower ATCS must contact the FAA agency flight surgeon or their AME before resuming pilot or contract tower ATCS duties
- The agency ATCS must contact the agency flight surgeon for clearance determination prior to resuming safety sensitive duties.
- For return to pilot or ATCS duties there must be no history of neurologic or psychiatric symptoms during and or after mefloquine use.